



School of Medicine

Department of Obstetrics and Gynecology

GRAND ROUNDS LECTURE SERIES



Kaitlin Burchett, MD

Gynecologic Oncology Fellow

Department of Obstetrics and Gynecology

Karmanos Cancer Institute /

Wayne State University School of Medicine

Detroit, MI

March 31, 2026

8:00 AM

“Common Presenting Vulvar Lesions and How to Manage from a GYN Oncologic Perspective”

Educational Objectives:

- Identify commonly presenting vulvar lesions and their epidemiology and pathophysiology, including infectious lesions, inflammatory dermatoses, common cysts, and precancerous and cancerous lesions.
- Discuss common first line treatments for the above conditions
- Discuss when biopsy is appropriate for the above conditions

Commercial Relationship Disclosure: None

Microsoft Teams Meeting

Meeting ID: 277 216 918 890 5

Passcode: UL3Ps27g

The Wayne State University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Wayne State University School of Medicine designates this live activity for a maximum of **1 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: Obstetricians and Gynecologist; Fellows, Residents, and Senior Staff of our affiliated hospitals, and physicians practicing in the community.

Department of Obstetrics and Gynecology Website Address: <http://www.obgyn.med.wayne.edu/>

For additional information contact: Alaina Bruce-Jackson at: (313) 993-4027, or email: abruce@med.wayne.edu

Commercial Relationship Disclosure:

Program Director: David R. Bryant Jr, MD, has none.

Planning Committee Members: Jeffrey R. Johnson, MD, Patrice Harold, MD, and Gil G. Mor, MD, PhD., have none.

Planning Committee Member: Jay M. Berman, MD is a consultant/speaker for: Bayer Healthcare, Gynesonics, Hologic, and Medtronic; a speaker for Organon; has research and is a speaker for ABBVIE and Myovant Sciences; and is also a consultant and has research for Pfizer

Any commercial relationships with ineligible companies have been mitigated

